Stockscreener 앱 받기
2.30
0.00%
0.00
시간 외 거래:
2.28
-0.02
-0.87%
전일 마감가:
$2.30
열려 있는:
$2.29
하루 거래량:
5.44M
Relative Volume:
2.42
시가총액:
$163.79M
수익:
$6.61M
순이익/손실:
$-36.33M
주가수익비율:
-4.4983
EPS:
-0.5113
순현금흐름:
$-37.93M
1주 성능:
+14.43%
1개월 성능:
+51.32%
6개월 성능:
+90.08%
1년 성능:
+381.17%
1일 변동 폭
$2.18
$2.42
1주일 범위
$1.885
$2.50
52주 변동 폭
$0.2425
$2.50
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.30 | 163.79M | 6.61M | -36.33M | -37.93M | -0.5113 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Roth Capital | Buy |
| 2025-11-17 | 개시 | Leerink Partners | Outperform |
| 2025-10-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-08 | 재개 | B. Riley Securities | Buy |
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Leerink reiterates Ovid Therapeutics stock rating on safety data By Investing.com - Investing.com Australia
Leerink reiterates Ovid Therapeutics stock rating on safety data - Investing.com
Ovid’s KCC2 direct activator OV-4071 cleared for clinic - BioWorld MedTech
Ovid Therapeutics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OVID) 2026-03-19 - Seeking Alpha
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN
Ovid Therapeutics Shares Surge After Positive Epilepsy Drug Trial Results - MSN
Ovid Therapeutics raises $60M, expands epilepsy drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics raises $60 million to expand drug development By Investing.com - Investing.com Canada
Ovid Therapeutics: Advancing Small Molecule Medicines for Epilepsy and Psychiatric Disorders – Pipeline, Strategy, and Company Overview - Minichart
Ovid Therapeutics (OVID) Q4 Profit Challenges Ongoing Loss Narrative - simplywall.st
Earnings Call Summary | Ovid Therapeutics(OVID.US) Q4 2025 Earnings Conference - 富途牛牛
Ovid Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Ovid Therapeutics Q4 Earnings Call Highlights - MarketBeat
Ovid Therapeutics 2025 10-K: $7.3M Revenue, $(17.41)M Net Loss - TradingView
OVID: 2025 saw higher revenue, reduced losses, and strong cash to support advancing CNS drug programs - TradingView
[10-K] Ovid Therapeutics Inc. Files Annual Report | OVID SEC FilingForm 10-K - Stock Titan
Ovid Therapeutics (OVID) Reports Strong Q4 Revenue and Expands C - GuruFocus
Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 - AlphaStreet
Here's Why Ovid Therapeutics Stock Popped Higher Today - The Globe and Mail
Here's Why Ovid Therapeutics Stock Popped Higher Today - The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Ovid Therapeutics Expands OV329 Epilepsy Program, Launches Phase 1 OV4071 Trial, and Reports Strong 2025 Financial Results - Minichart
Ovid Therapeutics Faces Market Uncertainty Amid Recent Earnings Review - StocksToTrade
Earnings call transcript: Ovid Therapeutics Q4 2025 Surprises with Earnings Beat - Investing.com
OVID’s Latest Strategic Moves Propel Stock Price Surge - timothysykes.com
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Benzinga
Ovid Therapeutics earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Ovid Therapeutics Inc. announced that it expects to receive $59.99992 million in funding from a group of investors - marketscreener.com
Ovid Therapeutics (OVID) Q4 Results Exceed Expectations for Earnings and Revenue - Bitget
Ovid (OVID) Reports Strong Cash Position as of Year-End 2025 - GuruFocus
Ovid Raises $60 Million in PIPE at $2.01, Including Pre-Funded Warrants - TradingView
Ovid Therapeutics (NASDAQ:OVID) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - Benzinga
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline - TipRanks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics raises $60M, expands epilepsy drug development - Investing.com
Ovid Therapeutics raises $60 million to expand drug development - Investing.com
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Ovid Therapeutics (NASDAQ: OVID) raises $60.0 million to fund epilepsy and KCC2 pipeline - Stock Titan
Ovid Therapeutics announces pricing of $60 million private placement - marketscreener.com
Ovid Therapeutics (OVID) Shares Surge on Positive Drug Results a - GuruFocus
Ovid Therapeutics Shares Surge Over 40% on Positive OV329 Drug Results - Intellectia AI
Ovid Therapeutics (OVID) Secures $60M in PIPE Financing - GuruFocus
Ovid Therapeutics (OVID) to Launch Phase 1 Trial for Novel Drug OV4071 - GuruFocus
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Secures $60 Million in PIPE Financing to Advance OV329 Development for Tuberous Sclerosis Complex and Infantile Spasms - Quiver Quantitative
Ovid funds new epilepsy and dementia trials through 2028 - Stock Titan
Ovid raises $60M to develop OV329 for tuberous sclerosis and infantile spasms - Stock Titan
Growth Recap: Does Ovid Therapeutics Inc have declining or rising EPS2026 Market Outlook & Safe Entry Point Identification - baoquankhu1.vn
Breakthrough in new drug development boosts market confidence: Ovid Therapeutics Inc. (NASDAQ: OVID) shares surged 26.4% in pre-market trading today after the company announced positive safety data for its experimental epilepsy drug OV935/TAK-935. - Bitget
Financial Data Highlights: Ovid Therapeutics Inc. (NASDAQ: OVID) reported in its latest financial statement that as of December 31, 2025, the company held a total of $90.4 million in cash, cash equivalents, and marketable securities. - Bitget
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):